Total Payments
$526,643
2024 Payments
$55,523
Companies
21
Transactions
241
Medicare Patients
2,105
Medicare Billing
$263,334
Payment Breakdown by Category
Consulting$344,736 (65.5%)
Research$94,114 (17.9%)
Travel$70,104 (13.3%)
Other$12,135 (2.3%)
Food & Beverage$5,555 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $344,736 | 63 | 65.5% |
| Unspecified | $94,114 | 45 | 17.9% |
| Travel and Lodging | $70,104 | 75 | 13.3% |
| Honoraria | $9,800 | 1 | 1.9% |
| Food and Beverage | $5,555 | 54 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,335 | 3 | 0.4% |
Payments by Type
General
$432,529
196 transactions
Research
$94,114
45 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $281,765 | 105 | $0 (2024) |
| Novo Nordisk Inc | $57,139 | 31 | $0 (2024) |
| Eli Lilly and Company | $46,875 | 53 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $32,084 | 6 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $16,688 | 5 | $0 (2017) |
| Ardelyx, Inc. | $11,200 | 1 | $0 (2022) |
| Medtronic, Inc. | $10,634 | 5 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $10,575 | 1 | $0 (2023) |
| AKEBIA THERAPEUTICS INC | $9,800 | 1 | $0 (2021) |
| Becton, Dickinson and Company | $9,800 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,523 | 38 | Novo Nordisk AS ($22,814) |
| 2023 | $137,948 | 53 | Novo Nordisk AS ($102,442) |
| 2022 | $77,475 | 25 | Novo Nordisk AS ($55,996) |
| 2021 | $48,305 | 10 | Novo Nordisk AS ($11,880) |
| 2020 | $36,672 | 13 | Novartis Pharmaceuticals Corporation ($11,088) |
| 2019 | $44,484 | 45 | Novo Nordisk Inc ($17,981) |
| 2018 | $83,677 | 34 | Novo Nordisk AS ($52,514) |
| 2017 | $42,559 | 23 | AstraZeneca Pharmaceuticals LP ($16,688) |
All Payment Transactions
241 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $472.39 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $289.10 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $289.10 | General |
| 11/12/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $8,662.50 | General |
| 11/12/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $6,296.87 | General |
| 11/12/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $728.36 | General |
| 11/12/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $495.95 | General |
| 11/12/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $419.54 | General |
| 11/04/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $1,040.58 | General |
| 11/04/2024 | Novo Nordisk AS | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| 11/04/2024 | Novo Nordisk AS | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| 11/04/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $388.09 | General |
| 11/04/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $372.15 | General |
| 11/04/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $164.11 | General |
| 11/04/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $46.00 | General |
| 11/01/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 09/04/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 05/10/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,639.00 | General |
| 05/07/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 04/09/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,525.00 | General |
| 04/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 03/19/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $202.65 | General |
| 03/15/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9536-4388 | Novo Nordisk AS | $93,211 | 38 |
| M16-100 | AbbVie, Inc. | $902.97 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 538 | 638 | $758,643 | $66,872 |
| 2022 | 14 | 511 | 632 | $571,225 | $64,074 |
| 2021 | 14 | 565 | 663 | $683,396 | $72,200 |
| 2020 | 14 | 491 | 575 | $621,653 | $60,189 |
Total Patients
2,105
Total Services
2,508
Medicare Billing
$263,334
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 106 | $175,854 | $17,582 | 10.0% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2023 | 75 | 75 | $198,450 | $11,972 | 6.0% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 18 | 21 | $88,767 | $8,798 | 9.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 114 | 122 | $51,058 | $8,043 | 15.8% |
| 93455 | Insertion of tube in bypass graft for diagnosis with review by radiologist | Facility | 2023 | 18 | 19 | $66,044 | $3,499 | 5.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 36 | 36 | $21,897 | $3,446 | 15.7% |
| 93456 | Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 15 | 15 | $60,900 | $3,391 | 5.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 28 | $16,378 | $2,879 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $11,032 | $1,797 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 45 | 45 | $12,240 | $1,661 | 13.6% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | Facility | 2023 | 18 | 19 | $12,407 | $1,377 | 11.1% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 110 | 112 | $29,904 | $1,088 | 3.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 12 | $5,088 | $730.80 | 14.4% |
| 93571 | Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | Facility | 2023 | 14 | 14 | $8,624 | $608.88 | 7.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 22 | 85 | $128,180 | $14,741 | 11.5% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2022 | 74 | 74 | $177,970 | $12,135 | 6.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 103 | 122 | $46,262 | $8,452 | 18.3% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2022 | 15 | 18 | $69,174 | $7,771 | 11.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 55 | $30,415 | $4,387 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 30 | 32 | $17,091 | $3,669 | 21.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $17,554 | $2,817 | 16.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 24 | 24 | $13,668 | $2,444 | 17.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $9,308 | $1,874 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 38 | 41 | $10,113 | $1,735 | 17.2% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | Facility | 2022 | 17 | 17 | $10,098 | $1,281 | 12.7% |
About Dr. Abraham Lincoff, MD
Dr. Abraham Lincoff, MD is a Cardiovascular Disease healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427141902.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abraham Lincoff, MD has received a total of $526,643 in payments from pharmaceutical and medical device companies, with $55,523 received in 2024. These payments were reported across 241 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($344,736).
As a Medicare-enrolled provider, Lincoff has provided services to 2,105 Medicare beneficiaries, totaling 2,508 services with total Medicare billing of $263,334. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Cleveland, OH
- Active Since 10/02/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1427141902
Products in Payments
- Wegovy (Drug) $87,711
- Saxenda (Drug) $52,514
- Ozempic (Drug) $23,706
- ILARIS (Biological) $20,996
- EPANOVA (Drug) $16,838
- ENTRESTO (Drug) $11,088
- AFX2 Bifurcated Endograft System (Device) $9,800
- Auryxia (Drug) $9,800
- LUTONIX (Device) $9,800
- MOUNJARO (Drug) $5,691
- Repatha (Biological) $2,028
- Androgel (Drug) $902.97
- IN.PACT Admiral (Device) $100.47
- NEXLETOL (Drug) $87.02
- ONYX FRONTIER (Device) $69.62
- Impella (Device) $21.66
- Resolute (Device) $17.54
- EUPHORA (Device) $12.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Cleveland
Guilherme Attizzani
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Walid Saliba, Md, MD
Cardiovascular Disease — Payments: $388,217
Cardiovascular Disease $388,217
Oussama Wazni, Md, MD
Cardiovascular Disease — Payments: $348,033
Cardiovascular Disease $348,033
Dr. Ian Neeland, Md, MD
Cardiovascular Disease — Payments: $340,386
Cardiovascular Disease $340,386
Steven Nissen, Md, MD
Cardiovascular Disease — Payments: $330,365
Cardiovascular Disease $330,365
Brian Hoit, Md, MD
Cardiovascular Disease — Payments: $290,243
Cardiovascular Disease $290,243